Biotech Boulevard
Startups and Spinouts
GEN's Biotech Boulevard highlights new entrepreneurial biotech firms based all over the globe. These unique companies are developing breakthrough products that will expand and enhance the biotech industry.
Discover, invest, and collaborate with these industry leaders of tomorrow.
Explore Biotech Boulevard. It's paved with opportunities!
GEN's Biotech Boulevard
All  All  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z   0  1  2  3  4  5  6  7  8  9   
  • Blueprint Medicines www.blueprintmedicines.com

    Blueprint Medicines is committed to improving the lives of cancer patients by transforming genomically-defined subsets of cancer from life-threatening diseases to manageable conditions. Blueprint Medicines is harnessing the potential of the cancer genomics revolution by rapidly translating emerging insights into impactful drug programs.

  • BlueSEQ www.blueseq.com

    BlueSEQ helps research labs, universities, hospitals, and genome centers around the world design and outsource next-generation sequencing projects. The company matches sequencing service needs with providers that have the right next-generation sequencing technology and expertise. BlueSEQ provides a neutral source of market and technical information to support optimal next-generation sequencing project design and service provider compatibility.

  • Cardeas Pharma www.cardeaspharma.com

    Cardeas is a privately held pharmaceutical company dedicated to the development and commercialization of inhaled antibiotics to treat serious, hospital-acquired respiratory infections with highly antibiotic-resistant organisms. By combining novel formulations of proven antibiotics with cutting edge drug delivery technology, Cardeas is addressing significant unmet medical needs in the critical-care setting.

     

  • Cardio3 BioSciences www.c3bs.com

    Cardio3 BioSciences is a biopharmaceutical company involved in the discovery, development, and commercialization of regenerative and protective therapies for cardiovascular diseases.The aim of these therapies is to protect the heart during myocardial injury, reduce the volume of the scar and reconstruct damaged heart tissue. The company’s product candidates and research programs are based on the proprietary Cardiopoiesis technology platform, which is based on fundamental research conducted at Mayo Clinic.

  • Catabasis www.catabasispharma.com

    Catabasis is a clinical stage company that develops products to target inflammatory, immunological and metabolic diseases. It's SMART linker platform technology produces new chemical entities that have amplified efficacy along a clinically validated disease pathway through the conjugation of two known products via a linker that is metabolized intracellularly in cells relevant to the particular disease.

  • Cellworks www.cellworksgroup.com

    Cellworks has built a pipeline of drug candidates for cancer and rheumatoid arthritis by implementing a novel approach to therapeutic design and development. The Cellworks approach combines a predictive and responsive network of protein interactions with sophisticated algorithms to emulate human physiology and predict clinical outcomes early on. The company is using this technology to design novel mechanism of actions by combining existing FDA approved drugs that work synergistically to impact multiple disease pathways simultaneously. 

  • Cleave Biosciences www.cleavebio.com

    Cleave Biosciences is discovering and developing novel small molecule therapies for difficult-to-treat cancers by targeting protein homeostasis through the ubiquitin proteasome and autophagy systems, an area of unrealized potential. Cleave is using molecular profiling approaches with the goal of identifying patient subsets most likely to benefit from each of its targeted drugs.

  • Curiox Biosystems www.curiox.com

    Curiox Biosystems develops and commercializes cellular assay systems. Its first product, the DropArray™ platform, is intended to accelerate the progress of basic research, drug discovery and diagnostics through the miniaturization and automation of bioassays. The Curiox DropArray platform allows scientists to perform low-volume cellular assays efficiently using adherent, weakly adherent and even non-adherent cells, achieving long-term on-plate incubations without evaporation. Curiox recently introduced the LT210 (low throughput) or HT200 (high throughput) DropArray Washing Stations to automate the task of adding or changing media and buffers.

  • CytomX www.cytomx.com

    CytomX is a biotechnology company focused on improving the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics. CytomX's Probody™ Platform represents a transformational drug discovery and development approach for antibodies, enabling improved specificity, increased efficacy and decreased toxicity. 

  • Dezima Pharma www.dezimapharma.com

    Dezima Pharma develops drugs to treat dyslipidemia, a major modifiable risk for cardiovascular disease. Its objective is to develop compounds from pre-clinical development to meaningful proof of concept in patients. Dezima will seek strategic partners to further development in the larger cardiovascular indications, and/or continue in-house development of its compounds in smaller, orphan-type indications. The Netherlands-based company was founded by Forbion Capital Partner and BioGeneration Ventures.

© 2012 Genetic Engineering & Biotechnology News. All Rights Reserved.
Back to www.genengnews.com